Table 6.
Sensitivity analysis of the incremental cost effectiveness of pregabalin versus gabapentin in the treatment of painful diabetic neuropathy and post herpetic neuralgia
| Parameter | Baseline | Sensitivity analysis | Cost per additional day with no or mild pain | Cost per QALY gained |
|---|---|---|---|---|
|
Gabapentin dose (mg) |
2400 |
1800 |
14 (8,19) |
23 786 (14266,33498) |
|
Gabapentin dose (mg) |
2400 |
1200 |
16 (9,24) |
30 241 (18086,44056) |
|
Costs considered |
All healthcare costs |
Medication cost only |
16 (14,18) |
25 683 (22812,29829) |
|
Pregabalin daily cost |
3.65 |
↑20% |
24 (18,34) |
39 063 (28704,54620) |
|
Pregabalin daily cost |
3.65 |
↓20% |
7 (2,14) |
11 075 (2944,23040) |
|
Weekly probability of PCP visit in relation to NeP |
No/mild: 0.25 |
↑20% |
14 (8,20) |
21 025 (11592,30710) |
| Moderate: 0.31 | ||||
| Severe: 0.48 | ||||
|
Weekly probability of PCP visit in relation to NeP |
No/mild: 0.25 |
↓20% |
13 (7,19) |
19 773 (10531,28687) |
| Moderate: 0.31 | ||||
| Severe: 0.48 | ||||
|
Health utility associated with pain severity |
No/mild: 0.64 |
↑20% |
13 (9,18) |
17 017 (10296,23936) |
| Moderate: 0.48 | ||||
| Severe: 0.27 | ||||
|
Health utility associated with pain severity |
No/mild: 0.64 |
↓20% |
14 (8,20) |
27 505 (15418,40596) |
| Moderate: 0.48 | ||||
| Severe: 0.27 |
Mean values in € (SE) 95% CI.
NeP – Neuropathic pain.
PCP – primary care physician.